Theophylline
- Generic Name
- Theophylline
- Brand Names
- Elixophyllin, Elixophylline, Pulmophylline, Quibron-T, Theo-24, Theolair, Uniphyl
- Drug Type
- Small Molecule
- Chemical Formula
- C7H8N4O2
- CAS Number
- 58-55-9
- Unique Ingredient Identifier
- 0I55128JYK
- Background
A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under several brand names such as Uniphyl and Theo...
- Indication
For the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis.
- Associated Conditions
- Asthma, Bronchitis, Bronchoconstriction, Bronchospasm, Chronic Obstructive Pulmonary Disease (COPD), Chronic bronchial inflammation
- Associated Therapies
- Airway secretion clearance therapy, Bronchodilation
Theophylline Treatment for Pseudohypoparathyroidism
- Conditions
- Interventions
- First Posted Date
- 2017-01-24
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 34
- Registration Number
- NCT03029429
- Locations
- 🇺🇸
Ashley Shoemaker, Nashville, Tennessee, United States
Association Study Between CYP1A2 Gene Polymorphisms and Metabolism of Theophylline
- Conditions
- Interventions
- First Posted Date
- 2017-01-09
- Last Posted Date
- 2022-03-17
- Lead Sponsor
- XiaoGuang Zou
- Target Recruit Count
- 110
- Registration Number
- NCT03015090
- Locations
- 🇨🇳
Kashgar 1st People's Hospital, Kashgar, Xinjiang, China
Longitudinal Cohort Study in Participants With Severe Asthma to Assess Biomarkers
- Conditions
- Interventions
- First Posted Date
- 2015-09-02
- Last Posted Date
- 2019-04-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 483
- Registration Number
- NCT02537691
- Locations
- 🇱🇻
Riga 1st hospital, outpatient clinic Bruninieks, Riga, Latvia
🇱🇻Clinical Hospital Gailezers; Dept of Pulmonology, Riga, Latvia
🇱🇻Latvian University postgraduate institute, Riga, Latvia
Helping Olfaction and Nutrition On Renal Replacement
- First Posted Date
- 2015-06-24
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 7
- Registration Number
- NCT02479451
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy)
- Conditions
- Interventions
- First Posted Date
- 2015-06-04
- Last Posted Date
- 2017-06-26
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 6
- Registration Number
- NCT02463409
- Locations
- 🇺🇸
Vanderbilt Unversity, Nashville, Tennessee, United States
Enhancement of Corticosteroid Efficacy in COPD
- First Posted Date
- 2015-01-16
- Last Posted Date
- 2018-06-19
- Lead Sponsor
- UConn Health
- Target Recruit Count
- 13
- Registration Number
- NCT02340520
- Locations
- 🇺🇸
UConnHealth, Farmington, Connecticut, United States
Effect of BIIL 284 BS on the Pharmacokinetics of Theophylline in Healthy Male Volunteers
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2014-10-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT02273440
Theophylline and Steroids in Chronic Obstructive Pulmonary Disease (COPD) Study
- Conditions
- Interventions
- First Posted Date
- 2014-10-10
- Last Posted Date
- 2021-08-12
- Lead Sponsor
- The George Institute
- Target Recruit Count
- 1670
- Registration Number
- NCT02261727
- Locations
- 🇦🇺
The George Institute for Global Health, Sydney, New South Wales, Australia
Theophylline, N-acetylcysteine, and Theophylline Plus N-acetylcysteine in Preventing Contrast-induced Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2014-03-17
- Last Posted Date
- 2014-03-17
- Lead Sponsor
- Isfahan University of Medical Sciences
- Target Recruit Count
- 96
- Registration Number
- NCT02088502
- Locations
- 🇮🇷
Chamran Hospital, Isfahan, Iran, Islamic Republic of
A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline
- Conditions
- Interventions
- First Posted Date
- 2014-03-06
- Last Posted Date
- 2019-05-03
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 15
- Registration Number
- NCT02080078
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.